Next Article in Journal
The Role of Short-Chain Fatty Acids, Particularly Butyrate, in Oncological Immunotherapy with Checkpoint Inhibitors: The Effectiveness of Complementary Treatment with Clostridium butyricum 588
Previous Article in Journal
Swine Colibacillosis: Analysis of the Gut Bacterial Microbiome
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 12
Issue 6
10.3390/microorganisms12061234
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Diagnostic Performance of a Molecular Assay in Synovial Fluid Targeting Dominant Prosthetic Joint Infection Pathogens

by
Jiyoung Lee
1,†,
Eunyoung Baek
1,†,
Hyesun Ahn
2,
Heechul Park
3,
Suchan Lee
2,* and
Sunghyun Kim
4,5,*
1
Department of Research & Development, DreamDX Inc., C001, 57, Oryundae-ro, Geumjeong-gu, Busan 46252, Republic of Korea
2
Joint & Arthritis Research Center, Himchan Hospital, 120, Sinmok-ro, Yangcheon-gu, Seoul 07999, Republic of Korea
3
Department of Clinical Laboratory Science, Hyejeon College, Daehak 1-gil, Hongseong-eup, Hongseong-gun 32244, Republic of Korea
4
Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan, Busan 46252, Republic of Korea
5
Next-Generation Industrial Field-Based Specialist Program for Molecular Diagnostics, Brain Busan 21 Plus Project, Graduate School, Catholic University of Pusan, Busan 46252, Republic of Korea
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Microorganisms 2024, 12(6), 1234; https://doi.org/10.3390/microorganisms12061234
Submission received: 7 May 2024 / Revised: 14 June 2024 / Accepted: 16 June 2024 / Published: 19 June 2024
(This article belongs to the Special Issue Molecular Techniques, Novel Biomarkers and Coagulation-Based Methods in the Diagnosis of Periprosthetic Joint Infections)
Browse Figures
Review Reports Versions Notes

Abstract

:
Prosthetic joint infection (PJI) is one of the most serious complications of joint replacement surgery among orthopedic surgeries and occurs in 1 to 2% of primary surgeries. Additionally, the cause of PJIs is mostly bacteria from the Staphylococcus species, accounting for more than 98%, while fungi cause PJIs in only 1 to 2% of cases and can be difficult to manage. The current gold-standard microbiological method of culturing synovial fluid is time-consuming and produces false-negative and -positive results. This study aimed to identify a novel, accurate, and convenient molecular diagnostic method. The DreamDX primer–hydrolysis probe set was designed for the pan-bacterial and pan-fungal detection of DNA from pathogens that cause PJIs. The sensitivity and specificity of DreamDX primer–hydrolysis probes were 88.89% (95% CI, 56.50–99.43%) and 97.62% (95% CI, 87.68–99.88%), respectively, compared with the microbiological method of culturing synovial fluid, and receiver operating characteristic (ROC) area under the curve (AUC) was 0.9974 (*** p < 0.0001). It could be concluded that the DreamDX primer–hydrolysis probes have outstanding potential as a molecular diagnostic method for identifying the causative agents of PJIs, and that host inflammatory markers are useful as adjuvants in the diagnosis of PJIs.

1. Introduction

Prosthetic joint infections (PJIs) are one of the most serious complications of joint replacement surgery [1], and occur in 1 to 2% of patients after primary and 4% of patients after revision surgeries [2]. According to medical claim data from the Korean Health Insurance and Review and Assessment (KHIRA), between 2010 and 2018, the total number of joint replacement surgeries in the Republic of Korea increased from 72,766 to 106,933, PJIs increased from 1786 to 2989 per year, and the incidence of PJIs ranged from 2.3% to 2.8% and steadily increased over time [3,4].
Risk factors that increase the incidence of PJIs include rheumatoid arthritis, obesity, and diabetes. Causes of aseptic failure include screw loosening, fracture of or around the prosthesis, wear, poor implant placement, and poor material [5]. Many patients with knee osteoarthritis (OA) have knee joint disorders. Several types of surgery can be used to treat this disorder, including revision to total knee arthroplasty (TKA) after failed high tibial osteotomy (HTO) or unicompartmental knee arthroplasty (UKA) [6,7].
PJIs are currently diagnosed using the criteria proposed by the Musculoskeletal Infection Society (MSIS) [8]. The MSIS and the Infectious Disease Society developed these criteria to establish a standardized and clear definition of PJIs, improving diagnostic reliability and research collaboration. The major diagnostic criteria include two positive cultures of the same organism, a sinus tract with evidence of communication to the joint, or visualization of the prosthesis. The minor diagnostic criteria include preoperative symptoms, scored per symptom and determined as infected, possibly infected, or uninfected based on elevated serum C-reactive protein (CRP) or D-dimer levels, high serum erythrocyte sedimentation rate (ESR), high synovial white blood cell (WBC) count, synovial leukocyte esterase level (LE), synovial-positive alpha-defensin, high synovial polymorphonuclear cells (PMNs), and high synovial CRP levels. Intraoperative diagnosis is also scored per symptom and determined as infected, inconclusive, or uninfected, according to the score, preoperative score, positive histology, positive purulence, and single positive culture [9,10].
According to the time of onset and symptoms, PJIs are divided into early and delayed infections, which are classified as acute and chronic, respectively. An early infection is an acute PJI with clear signs of local and systemic inflammation. The most prevalent and virulent pathogens, such as Staphylococcus aureus, some Gram-negative bacteria, streptococci, and enterococci, cause early infections. Delayed infection causes chronic PJIs, which present with clinical symptoms such as chronic joint pain and premature loosening, and are caused by organisms with low virulence, such as coagulase-negative staphylococci (CoNS) and Cutibacterium species [11,12,13]. According to some previous reports [14,15], microorganisms that cause PJIs can be classified into monomicrobial and polymicrobial types, which cover various pathogens, including aerobic bacteria and fungi. The monomicrobial causes of PJIs are primarily S. epidermidis and S. aureus, followed by Streptococcus species and Gram-negative bacilli, enterococci, and CoNS. In another study, the pathogens identified after synovial fluid (SF) culture were CoNS, S. aureus, Streptococcus spp., Gram-negative rods, Enterococcus spp., anaerobes, and other pathogens, including Candida albicans and C. parapsilosis [14,15]. Additionally, the cause of PJIs is mostly bacteria from the Staphylococcus species, accounting for more than 98%, while fungi cause PJIs in only 1 to 2% of cases and can be difficult to manage, and Candida species are the most common (85%) [16,17,18].
To diagnose PJIs, microorganisms in SF are cultured and identified; however, this is time-consuming [19]. Therefore, most clinicians use conservative management with empiric antibiotic therapy. Moreover, infections related to microbial causes after total hip arthroplasty (THA) are difficult to diagnose and often require multiple diagnostic methods [20,21]. Currently, PJIs are classified according to the MSIS criteria, and are diagnosed as MSIS-defined culture-positive PJIs when the culture is positive [19]. Despite the availability of various tests, there are limitations in diagnosing PJIs when the culture is negative, and the effectiveness of antibiotics is often limited. Moreover, standardized clinical and evidence-based guidelines for the diagnosis of PJI are lacking; therefore, novel, advanced molecular diagnostic tests would be beneficial [9,22]. To overcome these limitations, various studies have investigated non-culture-based methods. Molecular diagnostic methods, such as quantitative polymerase chain reaction (qPCR), are being established in clinical laboratories and can be combined with existing methods to rapidly, specifically, and sensitively detect causative pathogens of PJIs in SF. However, the above issues have not yet been resolved.
Therefore, the present study aimed to develop a qPCR hydrolysis probe assay targeting bacterial 16S rRNA and fungal 18S rRNA genes to detect and differentiate pan-bacterial and pan-fungal pathogens of PJIs in SF. The result of qPCR hydrolysis probe assay was compared with microbial culture, 16S rRNA and ITS sequence analysis, and host’ acute phase indicators. Further, the study demonstrated that this probe assay is capable of generating rapid, highly sensitive, and specific results for the direct simultaneous detection of bacterial and fungal pathogens.

2. Materials and Methods

2.1. Patients and Samples

In total, 93 SF clinical samples were obtained from patients (TKA, HTO, or UKA) who had symptomatic osteoarthritis (OA). The samples were collected at Mokdong Hospital (Seoul, Republic of Korea) and Incheon Himchan Hospital (Incheon, Republic of Korea) between January 2022 and May 2023. This study was approved by the Institutional Review Board (IRB) of the Catholic University of Pusan (Approval No. CUPIRB-2022-01-006). Blood samples from patients were retrospectively analyzed using hospital data. SF samples from postoperative patients were aseptically collected using a sterilized syringe and aliquoted into sterilized conical tubes for plate culture, inflammation marker analysis, and DNA quantification. The samples were stored frozen until use. For culture, the SF samples were inoculated on blood agar plates using a sterilized cotton swab and incubated at 37 °C for 18–24 h. Growth covering up to 25% of the plate was considered “few”, up to 75%, “moderate”, and more than 75%, “numerous”.

2.2. Genomic DNA Extraction from Reference Strains and SF Samples

Genomic DNA was extracted from reference strains and SF samples using a Gentra Puregene Blood Kit (Qiagen, Hilden, Germany). One milliliter of sample was mixed with five milliliters of cell lysis solution and incubated at 65 °C for 15 min. Then, 30 µL of RNase A solution was added and the samples were incubated at 37 °C for 30 min. After mixing with 2 mL of protein precipitation solution, the samples were cooled on ice for 5 min and centrifuged at 2000× g for 10 min to precipitate the proteins. The supernatants were mixed with 6 mL of isopropanol, incubated at room temperature (RT) for 5 min, and centrifuged at 2000× g for 10 min to precipitate the DNA. After washing the DNA pellet with 6 mL of 70% ethanol and air-drying for 10 min, 200 µL of DNA hydration solution was added to dissolve the DNA at 65 °C for 1 h. The samples were gently shaken at RT overnight, transferred into 1.5 mL sterilized microcentrifuge tubes (Axygen, Corning, NY, USA), and stored at −20 °C.

2.3. Identification of Microorganisms Isolated from SF

Microorganisms in SF were identified using the VITEK 2 system (BioMérieux, La Balme-les-Grottes, France) per the manufacturer’s instructions.

2.4. Inflammation Marker Analysis

Serum total protein (TP) and CRP levels, the ESR, and whole-blood and SF WBC counts were determined. Serum TP and CRP levels were measured using a LABOSPECT 006 automatic analyzer (Hitachi High-Tech, Tokyo, Japan). The ESR and whole-blood WBC counts were measured using an XN-1000 hematology analyzer (Sysmex Corporation, Hyogo, Japan).

2.5. Bacterial and Fungal Pathogen-Specific Primer and Probe Design

To detect the causative pathogens of PJIs, we designed qPCR primer pairs and hydrolysis probes specific for 16S rRNA and 18S rRNA genes. The 16S rRNA gene target sequence was selected in a conserved region shared by dominant PJI bacterial species, including S. epidermidis, S. aureus, Enterococcus faecalis, Streptococcus dysgalactiae, Streptococcus pyogenes, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter cloacae. The 16S rRNA sequences of S. epidermidis (NCBI accession No. NR_036904.1), S. aureus (NR_118997.2), E. faecalis (MF108410.1), S. dysgalactiae (NR_027517.1), S. pyogenes (MT535878.1), E. coli (NR_024570.1), A. baumannii (NR_026206.1), P. aeruginosa (NR_026078.1), and E. cloacae (NR_102794.2) were aligned to confirm similarity. Similarly, the 18S rRNA gene target sequence was selected in a conserved region shared by dominant PJI fungal species, including C. glabrata, C. albicans, C. tropicalis, and C. parapsilosis, and the 18S rRNA gene sequences of C. glabrata (JF825465.1), C. albicans (LC612900.1), C. tropicalis (KX664670.1), and C. parapsilosis (LC643454.1) were aligned to confirm similarity (Figure 1 and Table S1). Primer pairs and hydrolysis probes with slight mismatches were designed using Clustal Omega Tools (https://www.ebi.ac.uk/jdispatcher/msa/clustalo; accessed on 15 June 2024) (EMBL-EBI, Hinxton, UK) and evaluated for secondary structures and dimer-forming potential using the IDT Oligo Analyzer Tools (https://sg.idtdna.com/calc/analyzer; accessed on 15 June 2024) (Integrated DNA Technologies, Coralville, IA, USA). The primer–probe sequence sets exhibiting the fewest secondary structures and lowest dimer-forming potential were selected for use in qPCR and were synthesized at Macrogen Institute (Seoul, Republic of Korea). The forward and reverse primers for pan-bacterial detection amplified 280 bp of the 16S rRNA gene, and the pan-bacterial-specific fluorescent and hydrolysis probes were designed within this region. The primers for pan-fungal detection amplified 161 bp of the 18S rRNA gene, encompassing the pan-fungal-specific fluorescent and hydrolysis probes. Because the causative pathogens of PJIs (9 bacteria and 4 fungi) had similar sequences, bacteria and fungi had to be detected discriminately without overlapping, so the conserved target area was wide, and the amplicon size was relatively large. Also, we had to find common regions in the sequences of the target bacteria and fungi that had no cross-reactivity and had high specificity, respectively. Therefore, hydrolysis probes were designed to increase sensitivity.

2.6. qPCR Hydrolysis Probes Assay

The qPCR hydrolysis probe assay (Dream Dx, Busan, Republic of Korea) was optimized to detect the 16S rRNA and 18S rRNA target genes of the dominant PJI-causing bacterial and fungal species. qPCRs were run in 20 μL reaction mixtures containing 10 μL 2 × Thunderbird probe qPCR mixture (Toyobo, Osaka, Japan), 1.0 μL forward primer (10 pmol), 1.0 μL reverse primer (10 pmol), 1.0 μL probe (1 pmol), 2.0 μL template DNA (50–100 ng/µL), and 5.0 μL distilled water. The thermal cycles were as follows: 95 °C for 10 min, 40 cycles of 95 °C for 15 s, 58 °C for 30 s, and 72 °C for 30 s. The efficacy of the DreamDX primer–probe set for the 93 clinical SF samples was confirmed by running qPCRs under the same conditions using reference strains such as ATCC and KCTC (Table S2) as controls and distilled water as a no-template control (NTC).
In cross-reactivity tests using bacterial and fungal reference strains, results were unreliable at a cycle threshold (Ct) value ≥ 30. Therefore, in this study, the cut-off Ct value was set at 30.
To validate clinical SF samples, the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) housekeeping gene was amplified using a primer–hydrolysis probe set [23]. GAPDH-negative samples with a Ct value ≥ 30 were omitted from the analysis (Table 1).

2.7. Determination of the Limit of Detection (LOD)

The LODs of the respective pan-bacterial and pan-fungal primer–hydrolysis probes set designed in this study were determined using synthetic plasmids for 16S rRNA and 18S rRNA genes (Macrogen Institute) of the nine selected dominant bacterial strains and four selected dominant fungal strains, respectively. The synthetic DNA samples were measured for absorbance using a NanoDrop™ 2000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and gene copies were quantified using a web-based DNA copy number and dilution calculator (https://www.thermofisher.com/kr/ko/home/brands/thermo-scientific/molecular-biology/molecular-biology-learning-center/molecular-biology-resource-library/thermo-scientific-web-tools/dna-copy-number-calculator.html; accessed on 15 June 2024) that computes the number of gene copies based on the measured absorbance.

2.8. 16S rRNA and ITS Sequencing Using DreamDX and Universal Primers

The universal primers 27F/1492R and ITS1F/ITS4R (Table S3) [24,25] were used to compare and confirm the results of microorganism identification of the reference strains and in clinical SF samples. The sequencing was conducted and analyzed at the Macrogen Institute, using Sanger sequencing in an ABI3730xl automated DNA analyzer (Thermo Fisher Scientific).

2.9. Analysis of the Specificity of the PJI Molecular Diagnostic Assay

To confirm that the probes detected no non-specific substances in samples, specificity was tested using target and non-target substances. Optimized qPCR hydrolysis probe assay was performed on nine bacterial and four fungal reference strains: ATCC 35989, ATCC 29213, KCTC 3511, KCTC 3098, ATCC 19615, ATCC 35150, KCTC 23254, KCTC 22063, ATCC 2361, KCTC 7653, KCTC 7212, KCTC 7219, and ATCC 10231.

2.10. Statistical Analysis

Statistical analyses were conducted using GraphPad Prism version 8 (GraphPad Software, San Diego, CA, USA) to determine differential DNA expression. Receiver operating characteristic (ROC) curves and areas under the ROC curves (AUCs) were used to assess the potential of using SF DNA as a diagnostic sample for PJIs. p-values < 0.05 were considered statistically significant.

3. Results

3.1. Patients and Clinical Samples

Between January 2022 and May 2023, SF samples were collected from 93 patients suspected of PJIs by direct puncture from the knee joints (Table 2). The mean age of the patients was 67.0 ± 13.50 years (range, 20–88 years).

3.2. Bacterial Culture Results and Prevalence of Bacterial Pathogens in SF Samples

Among the 93 SF samples, 9 (9.7%) tested positive (CP) in bacterial culture, 84 (90.3%) tested negative (CN) in bacterial culture, and 93 (100.0%) were fungal CN. Among the nine bacterial CP samples, six (66.7%) and three (33.3%) samples comprised Gram-positive (S. aureus, S. epidermidis, and S. dysgalactiae) and Gram-negative bacteria (E. coli, S. marcescens, and E. aerogenes), respectively. Colony counts of the nine bacterial CP samples were “few” in three (33.3%) cases, “moderate” in two (22.2%) cases, and “numerous” in four (44.4%) cases (Table S4).

3.3. LOD of the qPCR Hydrolysis Probes Assay for PJI Diagnosis

To establish a standard curve to evaluate sensitivity, recombinant plasmid DNA concentrations (Table S5) were established to range from 1 × 108 copies/µL to 1 × 101 copies/µL by 10-fold serial dilution. qPCRs for sensitivity determination were run in duplicate. A standard curve was constructed based on the Ct values for the samples and used to quantify each sample. The standard curves revealed good linearity of amplification, with the following correlation coefficients: S. epidermidis (R2 = 0.992), S. aureus (R2 = 0.992), E. faecalis (R2 = 0.993), S. dysgalactiae (R2 = 1.000), S. pyogenes (R2 = 0.995), E. coli (R2 = 0.998), A. baumannii (R2 = 0.993), P. aeruginosa (R2 = 0.999), E. cloacae (R2 = 0.999), C. glabrata (R2 = 0.999), C. albicans (R2 = 0.998), C. tropicalis (R2 = 0.993), and C. parapsilosis (R2 = 0.998) (Figure 2). The overall LOD of the assay was 102–103 copies/µL (Table 3).

3.4. Specificity of the qPCR Hydrolysis Probe Assay for PJI Diagnosis

The effectiveness and specificity of the DreamDX primer–hydrolysis probe set for pan-bacterial and pan-fungal detection were verified by qPCR hydrolysis probe assay using 13 reference strains. As cross-reactivity between the bacteria and fungi was not observed during target strain detection, all nine bacterial and four fungal reference strains were used as templates for qPCR (Table S2). The qPCR assay using the pan-bacterial DreamDX primer–hydrolysis probe set amplified the 16S rRNA genes of the nine bacterial reference pathogens and did not amplify the 18S rRNA genes of the fungal reference pathogens, whereas the qPCR assay using the pan-fungal primer–probe set amplified the 18S rRNA genes of the four dominant fungal pathogens, but not the 16S rRNA genes of the bacterial reference strains (Figure 3), indicating high assay specificity for the target bacterial and fungal pathogens. To confirm accuracy, qPCR products for the nine bacterial and four fungal reference strains were sequenced using DreamDX primers for pan-bacterial/fungal detection and the universal primers 27F and 1492R and ITS1F and ITS4R, respectively (Table 4). The results confirmed that the DreamDX primers for pan-bacterial/fungal detection designed in this study and the universal primers amplified all nine bacterial and four fungal reference strains, and the sequences of the products amplified using each primer set completely matched those of the reference strains.

3.5. Clinical Utility of the qPCR Hydrolysis Probe Assay for the Detection of Bacterial Pathogens Causing PJIs in Uncultured SF

In molecular biology, housekeeping genes are typically constitutive genes and required in basic cell maintenance function [26,27,28]. To monitor the efficiency of nucleic acid extraction and the potential presence of PCR inhibitors during the analysis, primer and hydrolysis probe sets were designed to detect GAPDH gene as an internal control. All 93 SF samples were tested using GAPDH primers and hydrolysis probes described elsewhere [23] and validated using GAPDH qPCR. In total, 45.16% (42/93) were GAPDH-negative and were therefore omitted from analysis, and the 51 (54.84%) GAPDH-positive samples were used for analysis.
After validation, based on the culture results and identification using the VITEK 2 system, they were identified as nine (9.68%) bacterial CPs and 42 (45.16%) bacterial CNs. According to the results of DreamDX qPCR for pan-bacterial detection, 10 (10.75%) samples tested bacterial qPCR-positive, and 41 (44.09%) tested qPCR-negative (Figure 4), and DreamDX qPCR for pan-fungal detection yielded negative results for all 51 (54.84%) samples. The sensitivity and specificity of the pan-bacterial DreamDX primers and probe for clinical SF samples were 88.89% (95% CI, 56.50–99.43%) and 97.62% (95% CI, 87.68–99.88%), respectively (Figure 5). ROC analysis showed excellent agreement between the culture and qPCR results (AUC 0.9974; *** p < 0.0001), confirming the validity of our assay.
We compared the accuracy of several methods, including the VITEK 2 system and 16S rRNA gene sequencing with the universal primers 27F/1492R and the DreamDX primers for pan-bacterial detection, using nine bacterial CP samples. The VITEK 2 identification results and sequencing results using universal primers and DreamDX primers for pan-bacterial detection were consistent (Table 5). The DreamDX primers for pan-bacterial detection were more effective than the universal primers in identifying bacterial species in clinical SF samples. Although the universal primers targeted a highly conserved 16S rRNA gene region, primer mismatches due to single-nucleotide variants [29,30] may have led to inconsistencies in the sequencing results. The results indicated that the DreamDX primers can be used to effectively detect PJI pathogens.
Finally, comparing the microorganism identification results with the sequencing results using DreamDX and universal primers, the same results were obtained using each primer, making it possible to detect PJI pathogens using DreamDX primers.

3.6. Comparison of Host Inflammation Marker Levels between Culture and Molecular Diagnostic Assay-Positive and -Negative Groups

To assess the differences in inflammatory factor levels between bacterial CP and CN samples, we compared TP and CRP levels in the serum, the ESR and WBC count in whole blood, and the WBC count in SF. The AUCs and p-values were 0.6042 (p = 0.4073) and 0.8000 (** p = 0.0035) for serum TP and CRP, respectively; 0.7908 (* p = 0.0247) and 0.7136 (* p = 0.0118) for ESR and WBC count in whole blood, respectively; and 0.9591 (*** p < 0.0001) for WBC count in SF (Figure 6 and Table S6).

4. Discussion

Artificial joint replacement surgery can improve joint function and relieve pain, thus enhancing patients’ quality of life [5]. With the recent trend of population aging, the number of artificial joint replacement surgeries has increased, as has the incidence of PJIs as associated complications.
Infection is currently determined based on the MSIS criteria [31,32]. The current gold standard is SF culture; however, this approach is time-consuming and may produce false-negative and false-positive (indicating the presence of a contaminant) results. Various PCR-based methods for the molecular diagnosis of infectious diseases have been developed and become mainstream [33]. These techniques enable rapid and sensitive detection of PJIs [34], do not suffer from culture contamination, can be useful for detecting uncultured or difficult-to-cultivate bacteria, and can increase the speed, sensitivity, and reliability of clinical diagnosis of causative agents [35]. However, molecular diagnosis remains susceptible to false-positive and false-negative results, and moreover, it is costly [36,37]. Therefore, a novel, accurate, simple, and convenient molecular diagnostic method for PJIs is required. The molecular diagnostic qPCR assay developed in this study required approximately 1.5 h, which is substantially less than the 24–48 h required to obtain a bacterial or fungal CP result from clinical SF samples [38]. The current criteria for diagnosing PJIs are based on both culture results and inflammatory factor levels [2,8,9,10,31,32]. In this framework, the molecular diagnostic assay developed in this study can be used as an auxiliary method.
VITEK 2 analysis of the 93 SF samples collected from two hospitals revealed nine bacterial CP results, namely, two (2.0%) cases of S. aureus, two (2.0%) cases of S. epidermidis, two (2.0%) cases of S. dysgalactiae, one (1.0%) case of E. coli, one (1.0%) case of Serratia marcescens, and one (1.0%) case of E. aerogenes (Table S4). In line with our findings, S. aureus, CoNS, Streptococcus spp., Enterococcus spp., Gram-negative bacteria, and anaerobes are typical bacterial pathogens that cause PJIs [39].
Around 1–4% of patients who undergo joint replacement surgery are diagnosed with PJIs [2,15,39]. In the present study, nine samples (9.7%) yielded bacterial CP results, and four (4.3%) were diagnosed with PJIs, which agrees with the findings in a previous study [2]. Fungal cultures of the SFs were all negative. Consistent herewith, fungal microorganisms are isolated in less than 1% of PJI cases [40]. Considering these and previous microorganism identification results in SF cultures, a more accurate differentiation of pathogens for PJI diagnosis is clearly needed to allow us to determine whether antibiotics or anti-fungal agents are indicated for treatment [16,17,18]. Metagenomic sequencing allows the analysis of rare microbial species or microbial species that are difficult to culture, and can analyze large amounts of microorganisms simultaneously. However, since information can be obtained from the entire genome, the analysis is costly and time-consuming. On the other hand, 16S rRNA sequencing is a technique that amplifies the target region and analyzes the sequence in parallel in large quantities. It has the advantage of being able to classify microorganisms down to the level of species and analyze them quickly, quantitatively, and at an economical price. In this study, dominant causative pathogens of PJIs (bacteria and fungi) could be detected using the target region of 16S rRNA and 18S rRNA genes, respectively.
In this study, we developed a qPCR diagnostic method to detect bacteria and fungi in SF using 16S rRNA and 18S rRNA genes, respectively, and evaluated its effectiveness. Prior to evaluating the qPCR diagnostic method, we had already established an accurate validation method for clinical SF samples using GAPDH as an internal control [23], which was then applied to all SF samples. In another study using GAPDH primers as an internal control, qPCR was performed, and nonamplified samples were excluded from case analysis [41]. Since the main causative pathogens (bacteria and fungi) of PJIs have already been identified, the method we developed is more useful for detecting them. Although 16S rRNA, 18S rRNA, and ITS sequence analysis is helpful in identifying bacteria and fungi that are difficult to identify by conventional methods [42,43,44], it has limitations such as the location and size of the amplified base sequence and limitations in discrimination between strains with high genetic identity [45,46]. However, since this is a technique that detects the DNA of the causative agents including bacteria and fungi, it can cause false positives due to DNA from very small amounts of contaminant agents or pathogens killed by already prescribed antibiotics. Therefore, the sensitivity that could be clinically significant was designated as the cut-off value. In addition, when the pathogen multiplied to a certain extent and the Ct was below 30, it could actually be clinically diagnosed as a PJI.
In the current study, the sensitivity and specificity of qPCR for the diagnosis of PJI were significantly higher than those reported in the previous study (73.3%, 95% CI: 66.7–79.2% and 95.5%, 95% CI: 84.5–99.4%, respectively) [47].
In addition, sequencing results using pan-bacterial DreamDX primers and hydrolysis probes were consistently concordant with the VITEK 2 identification data, with 100% sensitivity, specificity, and accuracy. The results of the pan-bacterial DreamDX primer–hydrolysis probe assay developed in this study in terms of CP-dominant PJI species were consistent with those in a previous study [39]. The sequencing and VITEK 2 identification results agreed very well between the pan-bacterial DreamDX and universal primers, with 100% (9/9) and 88.9% (8/9) accuracy, respectively. Potential reasons for inconsistent sequencing results in unmatched samples may include a low number of organisms in the SF, as indicated by the culture results (labeled as “few”) (Table 5), non-uniform distribution of organisms in the SF, PCR inhibitors present in the SF, or inefficient DNA extraction from the samples [48,49].
PJIs induce systemic and local inflammatory and immune responses around the implanted device. TP, CRP, ESR, and WBC count are widely used as host inflammatory markers [50,51]. In this study, serum CRP, whole-blood ESR, WBC count, and SF WBC count showed significant differences between the bacterial CP and bacterial CN groups, while serum TP values did not differ significantly between groups (Figure 5 and Table S6). Several studies have confirmed the diagnostic and predictive value of serum CRP, whole-blood ESR, WBC count, and SF WBC count as biomarkers [50,52,53].
Therefore, utilizing these host inflammatory markers as supplementary indicators can help to reduce the risk of false positives from skin flora in qPCR tests, enhancing their utility and enabling accurate diagnosis.
qPCR is subject to several limitations, including the potential for contamination. As the Taq polymerase used in qPCR is derived from E. coli, residual DNA remaining during the amplification process may be detected as a non-specific amplification product [54]. To overcome this limitation, we used sterile distilled water as a non-template control. Samples were classified as positive or negative based on a Ct cut-off value of 30 in this study. A second limitation specific to the present study was that all SF samples were collected retrospectively. As selection bias is more likely to affect retrospective studies [55], a prospective study using consecutive cases of PJIs should be conducted to offset this limitation [56]. Third, among the bacterial CP samples using SF, one of the three “few” samples exhibited low sensitivity, possibly due to an insufficient amount of template (Table 5) [57,58]. Fourth, although the DreamDX primer–hydrolysis probe set developed for this study is designed for pan-fungal detection and can distinguish between bacteria and fungi, its utility for clinical SF samples remains unconfirmed, as our study did not include fungal CP samples.
In conclusion, this study revealed that the DreamDX primers, designed to be pan-bacterial-specific, were more effective than the universal primers in detecting dominant bacteria causing PJIs. As PJI-causative bacterial pathogens can be detected using DNA extracted from SF, this assay has outstanding potential as a molecular diagnostic method. Additionally, we developed a new molecular diagnostic tool for detecting fungal pathogens in PJIs. However, this assay was tested using only fungal reference strains as a positive control and bacterial reference strains as a negative control as this study did not include clinical fungal-positive SFs; therefore, validation using fungal-positive clinical SF samples is necessary in further studies.

5. Patents

The work reported in this manuscript resulted in two patents: Composition for the detection of bacterial infection and detection method using the same (Korean Patent No. 10-2546046, PCT/KR2023/014223) and Composition for the detection of fungal infection and detection method using the same (Korean Patent No. 10-2546048, PCT/KR2023/014246).

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/microorganisms12061234/s1, Table S1: Accession numbers of the selected nine dominant PJI bacteria and four dominant PJI fungi; Table S2: Reference strains used in this study; Table S3: Sequences of universal primers used in this study; Table S4: Microorganism culture and identification; Table S5: 16S rRNA and 18S rRNA target gene sequences; Table S6: Serum TP level, CPR, whole-blood ESR and WBC count, and synovial fluid WBC count in the culture-positive and -negative groups.

Author Contributions

J.L. and E.B.: Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing—original draft, Writing—review and editing; H.A.: Resources, Writing—review and editing; H.P.: Resources, Writing—review and editing; S.K. and S.L.: Funding acquisition, Writing—review and editing Project administration, Supervision, Conceptualization. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by Busan Techno Park (Busan). Grant numbers and sources of support (including departmental or institutional funding when no extramural funding was received): Busan Techno Park.

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary material; further inquiries can be directed to the corresponding authors.

Conflicts of Interest

Jiyoung Lee and Eunyoung Baek are employees of DreamDX Inc., a company that aims to commercialize the presented real-time PCR-based molecular diagnostic assays. All other authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Li, C.; Ojeda-Thies, C.; Xu, C.; Trampuz, A. Meta-Analysis in Periprosthetic Joint Infection: A Global Bibliometric Analysis. J. Orthop. Surg. Res. 2020, 15, 251. [Google Scholar] [CrossRef]
  2. Izakovicova, P.; Borens, O.; Trampuz, A. Periprosthetic Joint Infection: Current Concepts and Outlook. EFORT Open Rev. 2019, 4, 482–494. [Google Scholar] [CrossRef]
  3. Kim, H.S.; Park, J.W.; Moon, S.Y.; Lee, Y.K.; Ha, Y.C.; Koo, K.H. Current and Future Burden of Periprosthetic Joint Infection from National Claim Database. J. Korean Med. Sci. 2020, 21, e410. [Google Scholar] [CrossRef]
  4. Ko, M.S.; Choi, C.H.; Yoon, H.K.; Yoo, J.H.; Oh, H.C.; Lee, J.H.; Park, S.H. Risk Factors of Postoperative Complications Following Total Knee Arthroplasty in Korea. Medicine 2021, 100, e28052. [Google Scholar] [CrossRef]
  5. Tande, A.J.; Patel, R. Prosthetic Joint Infection. Clin. Microbiol. Rev. 2014, 27, 302–345. [Google Scholar] [CrossRef]
  6. Takeuchi, R.; Umemoto, Y.; Aratake, M.; Bito, H.; Saito, I.; Kumagai, K.; Sasaki, Y.; Akamatsu, Y.; Ishikawa, H.; Koshino, T.; et al. A Mid Term Comparison of Open Wedge High Tibial Osteotomy vs. Unicompartmental Knee Arthroplasty for Medial Compartment Osteoarthritis of the Knee. J. Orthop. Surg. Res. 2010, 5, 65. [Google Scholar] [CrossRef]
  7. Fu, D.; Li, G.; Chen, K.; Zhao, Y.; Hua, Y.; Cai, Z. Comparison of High Tibial Osteotomy and Unicompartmental Knee Arthroplasty in the Treatment of Unicompartmental Osteoarthritis A Meta-Analysis. J. Arthroplast. 2013, 28, 759–765. [Google Scholar] [CrossRef]
  8. Ivy, M.I.; Thoendel, M.J.; Jeraldo, P.R.; Greenwood-Quaintance, K.E.; Hanssen, A.D.; Abdel, M.P.; Chia, N.; Yao, J.Z.; Tande, A.J.; Mandrekar, J.N.; et al. Direct Detection and Identification of Prosthetic Joint Infection Pathogens in Synovial Fluid by Metagenomic Shotgun Sequencing. J. Clin. Microbiol. 2018, 56, e00402-18. [Google Scholar] [CrossRef]
  9. Parcizi, J.; Tan, T.; Goswami, K.; Higuera, C.; Della Valle, C.; Chen, A.F.; Shohat, N. The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria. J. Arthroplast. 2018, 33, 1309–1314. [Google Scholar] [CrossRef]
  10. Chen, Y.; Kang, X.; Tao, J.; Zhang, Y.; Chenting, Y.; Lin, W. Reliability of Synovial Fluid Alpha-Defensin and Leukocyte Esterase in Diagnosing Periprosthetic Joint Infection (PJI): A Systematic Review and Meta-Analysis. J. Orthop. Surg. Res. 2019, 14, 453. [Google Scholar] [CrossRef]
  11. Zimmerli, W. Clinical Presentation and Treatment of Orthopaedic Implant-Associated Infection. J. Intern. Med. 2014, 276, 111–119. [Google Scholar] [CrossRef]
  12. Barrett, L.; Atkins, B. The Clinical Presentation of Prosthetic Joint Infection. J. Antimicrob. Chemother. 2014, 69 (Suppl. S1), i25–i27. [Google Scholar] [CrossRef]
  13. Triffault-Fillit, C.; Ferry, T.; Laurent, F.; Pradat, P.; Dupieux, C.; Conrad, A.; Becker, A.; Lustig, S.; Fessy, M.H.; Chidiac, C.; et al. Microbiologic Epidemiology Depending on Time to Occurrence of Prosthetic Joint Infection: A Prospective Cohort Study. Clin. Microbiol. Infect. 2019, 35, 353–358. [Google Scholar] [CrossRef]
  14. Rakow, A.; Perka, C.; Trampuz, A.; Renz, N. Origin and Characteristics of Haematogenous Periprosthetic Joint Infection. Clin. Microbiol. Infect. 2019, 25, 845–850. [Google Scholar] [CrossRef]
  15. Schulz, P.; Dlaska, C.E.; Perka, C.; Trampuz, A.; Renz, N. Preoperative Synovial Fluid Culture Poorly Predicts the Pathogen Causing Periprosthetic Joint Infection. Infection 2021, 49, 427–436. [Google Scholar] [CrossRef]
  16. Chisari, E.; Lin, F.; Fei, J.; Parvizi, J. Fungal Periprosthetic Joint Infection: Rare but Challenging Problem. Chin. J. Traumatol. 2022, 25, 63–66. [Google Scholar] [CrossRef]
  17. Gross, C.E.; Della Valle, C.J.; Rex, J.C.; Traven, S.A.; Durante, E.C. Fungal Periprosthetic Joint Infection: A Review of Demographics and Management. J. Arthroplast. 2021, 36, 1758–1764. [Google Scholar] [CrossRef]
  18. Sambri, A.; Zunarelli, R.; Fiore, M.; Bortoli, M.; Paolucci, A.; Filippini, M.; Zamparini, E.; Tedeschi, S.; Viale, P.; De Paolis, M. Epidemiology of Fungal Periprosthetic Joint Infection: A Systematic Review of the Literature. Microorganisms 2022, 11, 84. [Google Scholar] [CrossRef]
  19. Randau, T.M.; Molitor, E.; Fröschen, F.S.; Hörauf, A.; Kohlhof, H.; Scheidt, S.; Gravius, S.; Hischebeth, G.T. The Performance of a Dithiothreitol-Based Diagnostic System in Diagnosing Periprosthetic Joint Infection Compared to Sonication Fluid Cultures and Tissue Biopsies. Z. Orthop. Unfall. 2021, 159, 447–453. [Google Scholar] [CrossRef]
  20. Bonanzinga, T.; Zahar, A.; Dütsch, M.; Lausmann, C.; Kendoff, D.; Gehrke, T. How Reliable Is the Alpha-Defensin Immunoassay Test for Diagnosing Periprosthetic Joint Infection? A Prospective Study. Clin. Orthop. Relat. Res. 2017, 475, 408–415. [Google Scholar] [CrossRef]
  21. Gallo, J.; Kolar, M.; Dendis, M.; Loveckova, Y.; Sauer, P.; Zapletalova, J.; Koukalova, D. Culture and PCR Analysis of Joint Fluid in the Diagnosis of Prosthetic Joint Infection. New Microbiol. 2008, 31, 97–104. [Google Scholar]
  22. Gazendam, A.; Wood, T.J.; Tushinski, D.; Bali, K. Diagnosing Periprosthetic Joint Infection: A Scoping Review. Curr. Rev. Musculoskelet. Med. 2022, 15, 219–229. [Google Scholar] [CrossRef]
  23. Lee, J.Y.; Baek, E.Y.; Ahn, H.S.; Park, Y.N.; Kim, G.H.; Lim, S.A.; Lee, S.C.; Kim, S.H. Validation of Synovial Fluid Clinical Samples for Molecular Detection of Pathogens Causing Prosthetic Joint Infection Using GAPDH Housekeeping Gene as Internal Control. Biomed. Sci. Lett. 2023, 29, 220–230. [Google Scholar] [CrossRef]
  24. Weisburg, W.G.; Barns, S.M.; Pelletier, D.A.; Lane, D.J. 16S Ribosomal DNA Amplification for Phylogenetic Study. J. Bacteriol. 1991, 173, 697–703. [Google Scholar] [CrossRef]
  25. Xie, J.; Fu, Y.; Jiang, D.; Li, G.; Huang, J.; Li, B.; Hsiang, T.; Peng, Y. Intergeneric Transfer of Ribosomal Genes between Two Fungi. BMC Evol. Biol. 2008, 8, 87. [Google Scholar] [CrossRef]
  26. Nazet, U.; Schröder, A.; Grässel, S.; Muschter, D.; Proff, P.; Kirschneck, C. Housekeeping Gene Validation for RT-qPCR Studies on Synovial Fibroblasts Derived from Healthy and Osteoarthritic Patients with Focus on Mechanical Loading. PLoS ONE 2019, 14, e022579. [Google Scholar] [CrossRef]
  27. Zhang, X.; Ding, L.; Sandford, A.J. Selection of Reference Genes for Gene Expression Studies in Human Neutrophils by Real-Time PCR. BMC Mol. Biol. 2005, 6, 4. [Google Scholar] [CrossRef]
  28. Zainuddin, A.; Chua, K.H.; Abdul Rahim, N.; Makpol, S. Effect of Experimental Treatment on GAPDH mRNA Expression as a Housekeeping Gene in Human Diploid Fibroblasts. BMC Mol. Biol. 2010, 11, 59. [Google Scholar] [CrossRef]
  29. Sipos, R.; Székely, A.J.; Palatinszky, M.; Révész, S.; Márialigeti, K.; Nikolausz, M. Effect of Primer Mismatch, Annealing Temperature and PCR Cycle Number on 16S rRNA Gene-Targetting Bacterial Community Analysis. FEMS Microbiol. Ecol. 2007, 60, 341–350. [Google Scholar] [CrossRef]
  30. Ren, W.; Zhong, Y.; Ding, Y.; Wu, Y.; Xu, X.; Zhou, P. Mismatches in 16S rRNA Gene Primers: An Area Worth Further Exploring. Front. Microbiol. 2022, 13, 888803. [Google Scholar] [CrossRef]
  31. Parvizi, J.; Gehrke, T. Definition of Periprosthetic Joint Infection. J. Arthroplast. 2014, 29, 1331. [Google Scholar] [CrossRef]
  32. Yan, Q.; Karau, M.J.; Greenwood-Quaintance, K.E.; Mandrekar, J.N.; Osmon, D.R.; Abdel, M.P.; Patel, R. Comparison of Diagnostic Accuracy of Periprosthetic Tissue Culture in Blood Culture Bottles to That of Prosthesis Sonication Fluid Culture for Diagnosis of Prosthetic Joint Infection (PJI) by Use of Bayesian Latent Class Modeling and IDSA PJI Criteria for Classification. J. Clin. Microbiol. 2018, 56, e00319-18. [Google Scholar] [CrossRef]
  33. Weile, J.; Knabbe, C. Current Applications and Future Trends of Molecular Diagnostics in Clinical Bacteriology. Anal. Bioanal. Chem. 2009, 394, 731–742. [Google Scholar] [CrossRef]
  34. Cazanave, C.; Greenwood-Quaintance, K.E.; Hanssen, A.D.; Karau, M.J.; Schmidt, S.M.; Gomez Urena, E.O.; Mandrekar, J.N.; Osmon, D.R.; Lough, L.E.; Pritt, B.S.; et al. Rapid Molecular Microbiologic Diagnosis of Prosthetic Joint Infection. J. Clin. Microbiol. 2013, 51, 2280–2287. [Google Scholar] [CrossRef]
  35. Grijalva, M.; Horváth, R.; Dendis, M.; Erný, J.; Benedík, J. Molecular Diagnosis of Culture Negative Infective Endocarditis: Clinical Validation in a Group of Surgically Treated Patients. Heart 2003, 89, 263–268. [Google Scholar] [CrossRef]
  36. Lazic, I.; Feihl, S.; Prodinger, P.M.; Banke, I.J.; Trampuz, A.; von Eisenhart-Rothe, R.; Suren, C. Diagnostic Accuracy of Multiplex Polymerase Chain Reaction on Tissue Biopsies in Periprosthetic Joint Infections. Sci. Rep. 2021, 11, 19487. [Google Scholar] [CrossRef]
  37. Evans, S.R.; Hujer, A.M.; Jiang, H.; Hill, C.B.; Hujer, K.M.; Mediavilla, J.R.; Manca, C.; Tran, T.T.; Domitrovic, T.N.; Higgins, P.G.; et al. Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics to Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III. J. Clin. Microbiol. 2016, 55, 134–144. [Google Scholar] [CrossRef]
  38. Aggarwal, D.; Kanitkar, T.; Narouz, M.; Azadian, B.S.; Moore, L.S.P.; Mughal, N. Clinical Utility and Cost-Effectiveness of Bacterial 16S rRNA and Targeted PCR Based Diagnostic Testing in a UK Microbiology Laboratory Network. Sci. Rep. 2020, 10, 7965. [Google Scholar] [CrossRef]
  39. Rho, K.H.; Jeong, H.R.; Kim, S.H.; Choi, H.J.; Jung, S.J.; Son, H.J.; Han, S.H.; Choi, J.Y.; Kim, S.W.; Kim, H.B.; et al. The Korean Surgical Site Infection Surveillance System Report, 2018. Korean J. Healthc. Assoc. Infect. Control. Prev. 2020, 25, 128–136. [Google Scholar] [CrossRef]
  40. Ortega-Peña, S.; Colín-Castro, C.; Hernández-Duran, M.; López-Jácome, E.; Franco-Cendejas, R. Microbiological Characteristics and Patterns of Resistance in Prosthetic Joint Infections in a Referral Hospital. Cirugía Cir. 2015, 83, 371–377. [Google Scholar] [CrossRef]
  41. Fang, X.Y.; Li, W.B.; Zhang, C.F.; Huang, Z.D.; Zeng, H.Y.; Dong, Z.; Zhang, W.M. Detecting the Presence of Bacterial DNA and RNA by Polymerase Chain Reaction to Diagnose Suspected Periprosthetic Joint Infection after Antibiotic Therapy. Orthop. Surg. 2018, 1, 40–46. [Google Scholar] [CrossRef]
  42. Patel, J.B. 16S rRNA Gene Sequencing for Bacterial Pathogen Identification in the Clinical Laboratory. Mol. Diagn. 2001, 6, 313–321. [Google Scholar] [CrossRef]
  43. Embong, Z.; Hitam, W.H.W.; Yean, C.Y.; Rashid, N.H.A.; Kamarudin, B.; Abidin, S.K.Z.; Osman, S.; Zainuddin, Z.; Ravichandran, M. Specific Detection of Fungal Pathogens by 18S rRNA Gene PCR in Microbial Keratitis. BMC Ophthalmol. 2008, 8, 7. [Google Scholar] [CrossRef]
  44. Pryce, T.M.; Palladino, S.; Kay, I.D.; Coombs, G.W. Rapid Identification of Fungi by Sequencing the ITS1 and ITS2 Regions Using an Automated Capillary Electrophoresis System. Med. Mycol. 2003, 41, 369–381. [Google Scholar] [CrossRef]
  45. Sung, H.S.; Kim, M.N. Reliability of Sequence-Based Identification of Microorganism. Infect. Chemother. 2008, 40, 355–356. [Google Scholar] [CrossRef]
  46. Kim, Y.A.; Kang, E.W.; Moon, H.S.; Kim, D.W.; Yong, D.E. Application of 16S rRNA Gene-Targeted Next-Generation Sequencing for Bacterial Pathogen Detection in Continuous Ambulatory Peritoneal Dialysis Peritonitis. Ann. Clin. Microbiol. 2020, 23, wpr-816607. [Google Scholar] [CrossRef]
  47. Bémer, P.; Plouzeau, C.; Tande, D.; Léger, J.; Giraudeau, B.; Valentin, A.S.; Jolivet-Gougeon, A.; Vincent, P.; Corvec, S.; Gibaud, S.; et al. Evaluation of 16S rRNA Gene PCR Sensitivity and Specificity for Diagnosis of Prosthetic Joint Infection: A Prospective Multicenter Cross-Sectional Study. J. Clin. Microbiol. 2014, 52, 3583–3589. [Google Scholar] [CrossRef]
  48. Melendez, D.P.; Greenwood-Quaintance, K.E.; Berbari, E.F.; Osmon, D.R.; Mandrekar, J.N.; Hanssen, A.D.; Patel, R. Evaluation of a Genus- and Group-Specific Rapid PCR Assay Panel on Synovial Fluid for Diagnosis of Prosthetic Knee Infection. J. Clin. Microbiol. 2016, 54, 120–126. [Google Scholar] [CrossRef]
  49. Schaeverbeke, T.; Renaudin, H.; Clerc, M.; Lequen, L.; Vernhes, J.P.; De Barbeyrac, B.; Bannwarth, B.; Bébéar, C.; Dehais, J. Systematic Detection of Mycoplasmas by Culture and Polymerase Chain Reaction (PCR) Procedures in 209 Synovial Fluid Samples. Br. J. Rheumatol. 1997, 36, 310–314. [Google Scholar] [CrossRef]
  50. Choe, H.; Kobayashi, N.; Abe, K.; Hieda, Y.; Tezuka, T.; Inaba, Y. Evaluation of Serum Albumin and Globulin in Combination with C-Reactive Protein Improves Serum Diagnostic Accuracy for Low-Grade Periprosthetic Joint Infection. J. Arthroplast. 2023, 38, 555–561. [Google Scholar] [CrossRef]
  51. Falzarano, G.; Piscopo, A.; Grubor, P.; Rollo, G.; Medici, A.; Pipola, V.; Bisaccia, M.; Caraffa, A.; Barron, E.M.; Nobile, F.; et al. Use of Common Inflammatory Markers in the Long-Term Screening of Total Hip Arthroprosthesis Infections: Our Experience. Adv. Orthop. 2017, 2017, 9679470. [Google Scholar] [CrossRef]
  52. Kim, S.G.; Kim, J.G.; Jang, K.M.; Han, S.B.; Lim, H.C.; Bae, J.H. Diagnostic Value of Synovial White Blood Cell Count and Serum C-Reactive Protein for Acute Periprosthetic Joint Infection after Knee Arthroplasty. J. Arthroplast. 2017, 32, 3724–3728. [Google Scholar] [CrossRef]
  53. Society of Unicondylar Research and Continuing Education. Diagnosis of Periprosthetic Joint Infection after Unicompartmental Knee Arthroplasty. J. Arthroplast. 2012, 27, 46–50. [Google Scholar] [CrossRef]
  54. Miyamae, Y.; Inaba, Y.; Kobayashi, N.; Choe, H.; Ike, H.; Momose, T.; Fujiwara, S.; Saito, T. Quantitative Evaluation of Periprosthetic Infection by Real-Time Polymerase Chain Reaction: A Comparison with Conventional Methods. Diagn. Microbiol. Infect. Dis. 2012, 74, 125–130. [Google Scholar] [CrossRef]
  55. Lange, J.; Troelsen, A.; Søballe, K. Chronic Periprosthetic Hip Joint Infection. A Retrospective, Observational Study on the Treatment Strategy and Prognosis in 130 Non-Selected Patients. PLoS ONE 2016, 11, e0163457. [Google Scholar] [CrossRef]
  56. Kawamura, M.; Kobayashi, N.; Inaba, Y.; Choe, H.; Tezuka, T.; Kubota, S.; Saito, T. A New Multiplex Real-time Polymerase Chain Reaction Assay for the Diagnosis of Periprosthetic Joint Infection. Mod. Rheumatol. 2017, 27, 1072–1078. [Google Scholar] [CrossRef]
  57. Ma, L.; Chung, W.K. Quantitative Analysis of Copy Number Variants Based on Real-Time LightCycler PCR. Curr. Protoc. Hum. Genet. 2014, 80, 7.21.1–7.21.8. [Google Scholar] [CrossRef]
  58. Isham, I.M.; Najimudeen, S.M.; Cork, S.C.; Gupta, A.; Abdul-Careem, M.F. Comparison of Quantitative PCR and Digital PCR Assays for Quantitative Detection of Infectious Bronchitis Virus (IBV) Genome. J. Virol. Methods 2024, 324, 114859. [Google Scholar] [CrossRef]
Microorganisms 12 01234 g001aMicroorganisms 12 01234 g001b
Figure 1. Sequences and positions of (A) the nine dominant PJI bacteria-specific PCR primers and probes designed and used in this study for the 16S rRNA gene and (B) the four dominant PJI fungi-specific PCR primers and probes designed and used in this study for the 18S rRNA gene. Forward and reverse primer sequences are indicated with red frames, while probe sequences are indicated with green frames. The “*” character means that the residues or nucleotides are indicated identical conserved.
Figure 1. Sequences and positions of (A) the nine dominant PJI bacteria-specific PCR primers and probes designed and used in this study for the 16S rRNA gene and (B) the four dominant PJI fungi-specific PCR primers and probes designed and used in this study for the 18S rRNA gene. Forward and reverse primer sequences are indicated with red frames, while probe sequences are indicated with green frames. The “*” character means that the residues or nucleotides are indicated identical conserved.
Microorganisms 12 01234 g001aMicroorganisms 12 01234 g001b
Microorganisms 12 01234 g002aMicroorganisms 12 01234 g002bMicroorganisms 12 01234 g002c
Figure 2. Amplification curves and standard curves of target plasmids with concentrations of 1 × 108 copies/μL to 1 × 101 copies/μL. (A) Staphylococcus epidermidis, (B) Staphylococcus aureus, (C) Enterococcus faecalis, (D) Streptococcus dysgalactiae, (E) Streptococcus pyogenes, (F) Escherichia coli, (G) Acinetobacter baumannii, (H) Pseudomonas aeruginosa, (I) Enterobacter cloacae, (J) Candida glabrata, (K) Candida albicans, (L) Candida tropicalis, and (M) Candida parapsilosis.
Figure 2. Amplification curves and standard curves of target plasmids with concentrations of 1 × 108 copies/μL to 1 × 101 copies/μL. (A) Staphylococcus epidermidis, (B) Staphylococcus aureus, (C) Enterococcus faecalis, (D) Streptococcus dysgalactiae, (E) Streptococcus pyogenes, (F) Escherichia coli, (G) Acinetobacter baumannii, (H) Pseudomonas aeruginosa, (I) Enterobacter cloacae, (J) Candida glabrata, (K) Candida albicans, (L) Candida tropicalis, and (M) Candida parapsilosis.
Microorganisms 12 01234 g002aMicroorganisms 12 01234 g002bMicroorganisms 12 01234 g002c
Microorganisms 12 01234 g003aMicroorganisms 12 01234 g003b
Figure 3. Amplification plots of qPCR for nine bacterial and four fungal reference strains. X-axis: cycle numbers; Y-axis: relative fluorescence units (RFU). (A) Amplification curves generated using the pan-bacterial DreamDX primer–probe set for positive samples (Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus faecalis, Streptococcus dysgalactiae, Streptococcus pyogenes, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter cloacae), negative samples (Candida parapsilosis, Candida tropicalis, Candida glabrata, and Candida albicans), and distilled water used as a no-template control (NTC). (B) Amplification curves generated using the pan-fungal DreamDX primer–probe set for positive samples (C. parapsilosis, C. tropicalis, C. glabrata, and C. albicans), negative samples (S. epidermidis, S. aureus, E. faecalis, S. dysgalactiae, S. pyogenes, E. coli, A. baumannii, P. aeruginosa, and E. cloacae), and distilled water used as an NTC.
Figure 3. Amplification plots of qPCR for nine bacterial and four fungal reference strains. X-axis: cycle numbers; Y-axis: relative fluorescence units (RFU). (A) Amplification curves generated using the pan-bacterial DreamDX primer–probe set for positive samples (Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus faecalis, Streptococcus dysgalactiae, Streptococcus pyogenes, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter cloacae), negative samples (Candida parapsilosis, Candida tropicalis, Candida glabrata, and Candida albicans), and distilled water used as a no-template control (NTC). (B) Amplification curves generated using the pan-fungal DreamDX primer–probe set for positive samples (C. parapsilosis, C. tropicalis, C. glabrata, and C. albicans), negative samples (S. epidermidis, S. aureus, E. faecalis, S. dysgalactiae, S. pyogenes, E. coli, A. baumannii, P. aeruginosa, and E. cloacae), and distilled water used as an NTC.
Microorganisms 12 01234 g003aMicroorganisms 12 01234 g003b
Microorganisms 12 01234 g004
Figure 4. Flow diagram of sample selection based on GAPDH validation, microorganism identification, and pan-bacterial DreamDX qPCR results in PJI and non-PJI groups.
Figure 4. Flow diagram of sample selection based on GAPDH validation, microorganism identification, and pan-bacterial DreamDX qPCR results in PJI and non-PJI groups.
Microorganisms 12 01234 g004
Microorganisms 12 01234 g005
Figure 5. ROC curve of sensitivity (%) versus specificity (%) of the qPCR assay using the DreamDX primer–hydrolysis probe set for pan-bacterial detection of clinical SFs. The “***” character means that the p values less than 0.001.
Figure 5. ROC curve of sensitivity (%) versus specificity (%) of the qPCR assay using the DreamDX primer–hydrolysis probe set for pan-bacterial detection of clinical SFs. The “***” character means that the p values less than 0.001.
Microorganisms 12 01234 g005
Microorganisms 12 01234 g006
Figure 6. Inflammatory factor levels for CP and CN groups. (A) TP in serum, (B) CRP in serum, (C) erythrocyte sedimentation rate (ESR) in whole blood, (D) white blood cells (WBCs) in whole blood, and (E) white blood cells (WBCs) in synovial fluid. (F) Associations of inflammatory factors.
Figure 6. Inflammatory factor levels for CP and CN groups. (A) TP in serum, (B) CRP in serum, (C) erythrocyte sedimentation rate (ESR) in whole blood, (D) white blood cells (WBCs) in whole blood, and (E) white blood cells (WBCs) in synovial fluid. (F) Associations of inflammatory factors.
Microorganisms 12 01234 g006
Table 1. Validation of clinical SF samples using GAPDH.
Table 1. Validation of clinical SF samples using GAPDH.
GAPDH-Positive
(Ct < 30)		GAPDH-Negative
(Ct ≥ 30)		Total
Number of SF samples (n, %)51 (54.84%)42 (45.16%)93 (100%)
Ct value (mean ± SD)21.8 ± 4.2834.2 ± 2.7227.4 ± 7.17
Abbreviations: SF, synovial fluid; SD, standard deviation.
Table 2. Summary statistics of the clinical samples.
Table 2. Summary statistics of the clinical samples.
Bacterial CP
(n = 9, 100%)		Bacterial CN
(n = 84, 100%)		Total Patients and Fungal CN
(n = 93, 100%)
CharacteristicsMokdong Himchan Hospital
(n, %)		8 (88.9%)46 (54.8%)54 (58.1%)
Incheon Himchan Hospital
(n, %)		1 (11.1%)38 (45.2%)39 (41.9%)
Age (years; mean ± SD)67.7 ± 19.1866.9 ± 12.9167.0 ± 13.50
Female (n, %)3 (33.3%)44 (52.4%)47 (50.5%)
Male (n, %)6 (66.7%)40 (47.6%)46 (49.5%)
OASurgically treated group (n, %)8 (88.9%)40 (47.6%)48 (51.6%)
Non-surgically treated group (n, %)1 (11.1%)44 (52.4%)45 (48.4%)
Abbreviations: CP, culture-positive; CN, culture-negative; SD, standard deviation; OA, osteoarthritis.
Table 3. Sensitivity of the qPCR assay.
Table 3. Sensitivity of the qPCR assay.
OrganismPlasmid of Target StrainPlasmid DNA
Concentration		Ct ValueLog ValueLOD Concentration
BacteriaStaphylococcus epidermidis2.50 fg/μL29.512.938.42 × 102 copies/μL
Staphylococcus aureus2.50 fg/μL29.512.938.42 × 102 copies/μL
Enterococcus faecalis6.00 fg/μL29.562.867.31 × 102 copies/μL
Streptococcus dysgalactiae4.00 fg/μL28.542.969.19 × 102 copies/μL
Streptococcus pyogenes8.00 fg/μL29.432.887.53 × 102 copies/μL
Escherichia coli7.00 fg/μL28.613.011.03 × 103 copies/μL
Acinetobacter baumannii20.0 fg/μL28.573.887.55 × 103 copies/μL
Pseudomonas aeruginosa8.00 fg/μL28.562.969.19 × 102 copies/μL
Enterobacter cloacae7.00 fg/μL28.143.051.13 × 103 copies/μL
FungiCandida glabrata9.00 fg/μL28.942.979.29 × 102 copies/μL
Candida albicans7.00 fg/μL28.363.009.98 × 102 copies/μL
Candida tropicalis7.00 fg/μL28.312.846.91 × 102 copies/μL
Candida parapsilosis9.00 fg/μL27.988.958.85 × 102 copies/μL
Table 4. Results of sequencing using DreamDX primers for pan-bacterial and pan-fungal detection and universal primers (27F/1492R and ITS1F/ITS4R) for the reference strains.
Table 4. Results of sequencing using DreamDX primers for pan-bacterial and pan-fungal detection and universal primers (27F/1492R and ITS1F/ITS4R) for the reference strains.
Reference StrainSequencing PrimerAccession No.DescriptionMaximum ScoreTotal ScoreQuery CoverE ValuePercent Identified
Staphylococcus epidermidis
ATCC 35989		DreamDX primerKY442756.1Staphylococcus epidermidis strain RmS2T 16S ribosomal RNA gene, partial sequence43143141%1 × 10−11599.16%
Universal primerLC648288.1Staphylococcus epidermidis IRQBAS126 gene for 16S rRNA, partial sequence2058205898%0.099.38%
Staphylococcus aureus
ATCC 29213		DreamDX primerOQ626118.1Staphylococcus aureus strain 344 16S ribosomal RNA gene, partial sequence42942950%3.00 × 10−11598.37%
Universal primerAP028993.1Staphylococcus aureus TUM19959 DNA, complete genome1136826%9 × 10−2094.52%
Enterococcus faecalis
KCTC 3511		DreamDX primerMK791584.1Enterococcus faecalis strain CE_1_5 16S ribosomal RNA gene, partial sequence42542559%3 × 10−11497.60%
Universal primerHG799973.1Enterococcus faecalis partial 16S rRNA gene, isolate OCAT411984198496%0.096.67%
Streptococcus dysgalactiae subsp. equisimilis
KCTC 3098		DreamDX primerCP053074.1Streptococcus dysgalactiae subsp. equisimilis strain TPCH-A88 chromosome, complete genome401241128%1 × 10−10696.37%
Universal primerCP053074.1Streptococcus dysgalactiae subsp. equisimilis strain TPCH-A88 chromosome, complete genome182510,94899%0.099.70%
Streptococcus pyogenes
ATCC 19615		DreamDX primerLS483391.1Streptococcus pyogenes strain NCTC8320 genome assembly, chromosome: 1442265410%2 × 10−11899.59%
Universal primerHG316453.2Streptococcus pyogenes H293, complete genome1567937497%0.096.35%
Escherichia coli O157: H7
ATCC 35150		DreamDX primerCP123592.1Escherichia coli strain DJH_137 urine chromosome, complete genome427295357%1 × 10−11497.98%
Universal primerMT279578.1Escherichia coli strain E.Sa.12 16S ribosomal RNA gene, partial sequence2050205095%0.097.36%
Acinetobacter baumannii
KCTC 23254		DreamDX primerCP096717.1Acinetobacter baumannii strain 5741 chromosome, complete genome433257125%5 × 10−11698.77%
Universal primerLN611357.1Acinetobacter baumannii partial 16S rRNA gene, isolate 40312043204397%0.097.20%
Pseudomonas aeruginosa
KCTC 22063		DreamDX primerMK348744.1Pseudomonas aeruginosa strain EC8A23 16S ribosomal RNA gene, partial sequence4244246%1 × 10−11297.23%
Universal primerHM439417.1Pseudomonas aeruginosa strain PCP33 16S ribosomal RNA gene, partial sequence22622689%9 × 10−5472.19%
Enterobacter cloacae
ATCC 2361		DreamDX primerCP040827.1Enterobacter cloacae strain NH77 chromosome, complete genome407323653%1 × 10−10897.90%
Universal primerMN244518.1Enterobacter cloacae strain CP21 16S ribosomal RNA gene, partial sequence2174217495%0.098.16%
Candida glabrata
KCTC 7219		DreamDX primerOP150922.1Candida glabrata isolate D2RB internal transcribed spacer 1, partial sequence20720723%2 × 10−4896.83%
Universal primerON398731.1Candida glabrata isolate UDSMC8_ITS-1 internal transcribed spacer 1, partial sequence1537153767%0.0100%
Candida albicans ATCC 10231DreamDX primerKP675137.1Candida albicans strain H373A internal transcribed spacer 1, partial sequence21121138%9 × 10−5099.15%
Universal primerOK267909.1Candida albicans clone 13–20 internal transcribed spacer 1, partial sequence92892885%0.099.41%
Candida tropicalis KCTC 7212DreamDX primerOP143792.1Candida tropicalis isolate D4SDB internal transcribed spacer 1, partial sequence21133462%8 × 10−5099.15%
Universal primerAB467294.1Candida tropicalis gene for ITS1, strain: TL030181781798%0.096.22%
Candida parapsilosis KCTC 7653DreamDX primerMW703799.1Candida parapsilosis isolate IPFUNGSarsCov2-25 small subunit ribosomal RNA gene, partial sequence21521564%4 × 10−5197.64%
Universal primerMT153735.1Candida parapsilosis isolate 4Y137 internal transcribed spacer 1, partial sequence88788771%0.099.59%
Table 5. Ct values and sequencing results for the clinical SF samples.
Table 5. Ct values and sequencing results for the clinical SF samples.
No.OrganismQuantity of ColoniesCt Value
(Mean ± SD) 		Sequencing PrimerAccession No.DescriptionMaximum ScoreTotal ScoreQuery CoverE ValuePercent Identification
1Staphylococcus aureus
(Bacteria)		numerous26.1 ± 0.03DreamDX primerOQ626099.1Staphylococcus aureus strain 266 16S ribosomal RNA gene, partial sequence40940911%2 × 10−10898.29%
Universal primerMH447063.1Staphylococcus aureus strain B0020-03R 16S ribosomal RNA gene, partial sequence1306130688%0.090.72%
2 Staphylococcus aureus
(Bacteria)		numerous24.3 ± 0.3DreamDX primerOQ626118.1Staphylococcus aureus strain 344 16S ribosomal RNA gene, partial sequence41241237%4 × 10−11097.15%
Universal primerAP023034.1Staphylococcus aureus TPS3156 DNA, complete genome320189524%5 × 10−8286.05%
3 Streptococcus dysgalactiae
(Bacteria)		numerous17.0 ± 0.11DreamDX primerCP053074.1Streptococcus dysgalactiae subsp. equisimilis strain TPCH-A88 chromosome, complete genome427256624%2 × 10−11498.36%
Universal primerOP263260.1Streptococcus dysgalactiae subsp. equisimilis strain RERA134 16S ribosomal RNA gene, partial sequence1903190392%0.095.29%
4Escherichia coli
(Bacteria)		moderate20.5 ± 1.32DreamDX primerCP088766.1Escherichia coli strain B16EC0875 plasmid pB16EC0875-2, complete sequence44044025%3 × 10−11899.59%
Universal primerKP276714.1Escherichia coli strain UT1 16S ribosomal RNA gene, partial sequence1122112251%0.092.69%
5 Staphylococcus epidermidis
(Bacteria)		few29.2 ± 0.88DreamDX primerOR740675.1Staphylococcus epidermidis strain CM334 16S ribosomal RNA gene, partial sequence43643610%1 × 10−11699.17%
Universal primerFJ835669.1Uncultured bacterium clone YO00379D02 16S ribosomal RNA gene, partial sequence47947923%8 × 10−13099.25%
6 Staphylococcus epidermidis
(Bacteria)		few25.9 ± 0.99DreamDX primerOR740675.1Staphylococcus epidermidis strain CM334 16S ribosomal RNA gene, partial sequence43143194%4 × 10−11698.77%
Universal primer CP043804.1Staphylococcus epidermidis strain SESURV_p4_1553 chromosome1192712062%0.095.81%
7 Serratia marcescens
(Bacteria)		moderate20.3 ± 0.00DreamDX primerMN493799.1Serratia marcescens strain MKBn5e 16S ribosomal RNA gene, partial sequence43862650%1 × 10−11798.79%
Universal primerOM757735.1Serratia marcescens strain SEM 16S ribosomal RNA gene, partial sequence1334133475%0.090.56%
8 Streptococcus dysgalactiae
(Bacteria)		numerous17.3 ± 0.10DreamDX primerCP053074.1Streptococcus dysgalactiae subsp. equisimilis strain TPCH-A88 chromosome, complete genome433259929%4 × 10−11699.17%
Universal primerEF121441.1Streptococcus dysgalactiae strain 155719-2 16S ribosomal RNA gene, partial sequence1842184285%0.096.06%
9Klebsiella aerogenes
(Bacteria)		few24.3 ± 2.09DreamDX primerKU308267.1Klebsiella aerogenes strain B8 16S ribosomal RNA gene, partial sequence43843878%3 × 10−11899.18%
Universal primerKT998836.1Klebsiella aerogenes strain TIL_WAK_137 16S ribosomal RNA gene, partial sequence1247124768%0.096.24%
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lee, J.; Baek, E.; Ahn, H.; Park, H.; Lee, S.; Kim, S. Diagnostic Performance of a Molecular Assay in Synovial Fluid Targeting Dominant Prosthetic Joint Infection Pathogens. Microorganisms 2024, 12, 1234. https://doi.org/10.3390/microorganisms12061234

AMA Style

Lee J, Baek E, Ahn H, Park H, Lee S, Kim S. Diagnostic Performance of a Molecular Assay in Synovial Fluid Targeting Dominant Prosthetic Joint Infection Pathogens. Microorganisms. 2024; 12(6):1234. https://doi.org/10.3390/microorganisms12061234

Chicago/Turabian Style

Lee, Jiyoung, Eunyoung Baek, Hyesun Ahn, Heechul Park, Suchan Lee, and Sunghyun Kim. 2024. "Diagnostic Performance of a Molecular Assay in Synovial Fluid Targeting Dominant Prosthetic Joint Infection Pathogens" Microorganisms 12, no. 6: 1234. https://doi.org/10.3390/microorganisms12061234

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop